Description
Anti-CD18 Antibody, Non-Fucosylated (BioBet-334ZP) is a humanized monoclonal IgG1 antibody against CD18. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Unknown
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD18 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ITGB2
Full Name
Integrin Subunit Beta 2
Background
This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers. Integrins are integral cell-surface proteins that participate in cell adhesion as well as cell-surface mediated signalling. The encoded protein plays an important role in immune response and defects in this gene cause leukocyte adhesion deficiency. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014]
Alternative Names
Erlizumab;211323-03-4;rhuMAb CD18;rhuMAb;ITGB2;integrin, beta 2 (complement component 3 receptor 3 and 4 subunit);CD18, integrin, beta 2 (antigen CD18 (p95), lymphocyte function associated antigen 1;macrophage antigen 1 (mac 1) beta subunit) , MFI7;integr
Gene ID
3689
UniProt ID
P05107
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with ITGB2 include Leukocyte Adhesion Deficiency, Type I and Pertussis.
Related Pathways
Its related pathways are Integrin Pathway and Degradation of the extracellular matrix.
Function
Integrin ITGAL/ITGB2 is the receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin ITGAL/ITGB2 is also a receptor for the secreted ubiquitin-like protein ISG15; this interaction is mediated by ITGAL. The integrins ITGAM/ITGB2 and ITGAX/ITGB2 are the receptors of the third complement component iC3b fragment and fibrinogen. The integrin ITGAX/ITGB2 recognizes the G-P-R sequence in the alpha chain of fibrinogen. Integrin ITGAM/ITGB2 recognizes the P1 and P2 peptides of the fibrinogen-gamma chain. Integrin ITGAM/ITGB2 is also a receptor for factor x. Integrin ITGAD/ITGB2 is the receptor of ICAM3 and VCAM1. Contributes to natural killer cell toxicity. Participate in leukocyte adhesion and leukocyte transport, including T cells and neutrophils. Through PTK2B/pyk2-mediated activation, neutrophil migration is triggered during lung injury. The integrin ITGAL/ITGB2 is related to ICAM3, which contributes to the phagocytosis of macrophages and neutrophils. Related to the subunit ITGAM/CD11b, cd177-prtn3 is required for TNF-mediated neutrophil activation.
Post-translational modifications
Both Ser-745 and Ser-756 become phosphorylated when T-cells are exposed to phorbol esters. Phosphorylation on Thr-758 (but not on Ser-756) allows interaction with 14-3-3 proteins.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-334ZP
Description
Recombinant antibody Fragment F(ab')2 to CD18. Erlizumab, also known as rhuMAb, is a recombinant humanized monoclonal antibody that was an experimental immunosuppressive drug. Erlizumab treats heart attack, stroke, and traumatic shock.
Antibody Indication
Unknown
